Effectiveness and safety of different traditional Chinese medicines for Coronavirus disease 2019: A protocol for systematic review and network meta-analysis.

Introduction: The effectiveness of different Traditional Chinese Medicine in the treatment of COVID-19 is worthy of attention, but the efficacy and safety of different Traditional Chinese Medicine in the treatment of COVID-19 have not yet been compared, based on network meta-analysis.

Methods And Analysis: The 2 members independently searched 7 databases according to the retrieval strategy, and the retrieval time was from the beginning of the establishment of the database to June 19, 2021. Then the title was imported into the EndNote Software AQ8 (V.

Shensu IV prevents glomerular podocyte injury in nephrotic rats via promoting lncRNA H19/DIRAS3-mediated autophagy.

Shensu IV is a Chinese prescription well-known for its function in treating chronic kidney diseases. However, the potential mechanisms underlying how Shensu IV exerts its effects remain unclear. In the present study, we investigated the effects of Shensu IV on glomerular podocyte injury in nephrotic rats and puromycin-induced injury in cultured podocytes, and assessed the associated molecular mechanisms.

Reno-Protective Effect of Realgar Nanoparticles on Lupus Nephritis of MRL/Lpr Mice through STAT1.

Background: Realgar, an arsenic tetrasulfide compound, is a highly recognized traditional Chinese medicinal prescription that has been widely used to treat various diseases such as inflammatory diseases. However, there are still some problems in the clinical treatment of Realgar, such as large oral dose and high potential toxicity.

Objective: To evaluate effects of Realgar nanoparticles on lupus nephritis (LN) in vivo in MRL/lpr mice.